Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-09-18

Clinical Trial Update: A Study of Pertuzumab in Participants With Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of pertuzumab in prostate cancer was terminated; results were posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Perjeta (pertuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-09-18